Concord Biotech Limited reported its audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, following approval by the Board of Directors at its meeting held on May 29, 2026.
The Board recommended a dividend of Rs 7.55 per equity share of face value of Re 1 each for the financial year 2025-26. The dividend is subject to approval by shareholders at the ensuing Annual General Meeting.
Concord Biotech fixed July 24, 2026 as the record date to determine shareholders eligible to receive the dividend payment. The company also approved the Director's Report for the financial year ended March 31, 2026.
The Board appointed Mrs. Ekta Gupta as an Additional Independent Director with effect from June 1, 2026. Her appointment is for a term of five consecutive years, subject to shareholder approval.
Mrs. Gupta holds an MBA in Finance from Cardiff University and a B.Com (Hons) from Lady Shri Ram College, Delhi. She currently serves as Director at Sanghi Polymers Private Limited and has previously held roles with Deutsche Bank and in financial markets.
Concord Biotech's shares trade on the National Stock Exchange under the symbol CONCORDBIO and on BSE under scrip code 543960.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.